Press release content from Newswire. The AP news staff was not involved in its creation.
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
April 12, 2021 GMT
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
SIENA, Italy - April 12, 2021 - ( Newswire.com )
Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce a publication describing the construction of a DNA-encoded chemical library (DEL) that was successfully screened against multiple protein targets, yielding potent and selective small molecule binders against disease-relevant antigens.
Press release content from Newswire. The AP news staff was not involved in its creation.
Philogen Announces Participation to the 10th World Congress of Melanoma
April 12, 2021 GMT
Philogen Announces Participation to the 10th World Congress of Melanoma
SIENA, Italy - April 12, 2021 - ( Newswire.com )
Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce its participation in the 10th World Congress of Melanoma, a virtual event taking place from April 15 to 17, 2021.
Philogen, which is one of the sponsors of this congress, will give a poster presentation with the title: “A phase II study of intralesional Daromun (L19IL2 + L19TNF) in non-melanoma skin cancer patients with localized disease (NCT04362722)”. The poster will be on display for registered participants starting from Monday, April 12, 2021.
3 Min Read
ZURICH (Reuters) - Switzerland’s executive government on Monday urged voters to back the nation’s COVID-19 law, which is being challenged by people who fear it eases approval requirements for vaccines and has shifted too much political power away from parliament.
A Swiss flag is pictured on the Mont-Blanc bridge, amid the coronavirus disease (COVID-19) pandemic, in Geneva, Switzerland, March 8, 2021. Picture taken March 8, 2021. REUTERS/Denis Balibouse
With Switzerland’s direct democracy, voters go to the polls on June 13 to weigh in on whether the law to help combat the pandemic went too far. The seven-member executive on Monday agreed at a closed-door session to recommend to voters to back the law.
UPDATE 3-Spanish drugmaker Rovi to make ingredients for Moderna COVID-19 vaccine Reuters 9 hrs ago Rovi deepens role making Moderna vaccine
Popular Searches Rovi CEO: Deal a significant growth opportunity (Adds details about agreement)
By Emma Pinedo and John Miller
MADRID, April 12 (Reuters) - Contract drugmaker Rovi is to make active ingredients for Moderna s COVID-19 vaccine, extending an existing agreement to bottle the vaccine using ingredients brought in from Switzerland.
Madrid-based Rovi, whose shares rose 4% on Monday towards a record high set last month, will build capacity to supply active agents for up to 100 million vaccine doses annually for Moderna from its plant in the southern city of Granada via a new production line.